Emergent external ventricular drain placement in patients with factor Xa inhibitor-associated intracerebral hemorrhage after reversal with andexanet alfa

[1]  Kevin M. Wheelock,et al.  Clinician Trends in Prescribing Direct Oral Anticoagulants for US Medicare Beneficiaries , 2021, JAMA network open.

[2]  T. Ortel,et al.  Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage , 2021, Journal of Thrombosis and Thrombolysis.

[3]  G. Falcone,et al.  Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage , 2021, Neurocritical Care.

[4]  T. Trujillo,et al.  Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding , 2021, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[5]  M. Concha,et al.  An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage , 2020, Clinical Neurology and Neurosurgery.

[6]  P. Dobesh,et al.  Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study. , 2020, Future cardiology.

[7]  Aman B Patel,et al.  Evaluation of andexanet alfa and four‐factor prothrombin complex concentrate (4F‐PCC) for reversal of rivaroxaban‐ and apixaban‐associated intracranial hemorrhages , 2020, Journal of thrombosis and haemostasis : JTH.

[8]  P. Dobesh,et al.  Antidotes for reversal of direct oral anticoagulants. , 2019, Pharmacology & therapeutics.

[9]  J. Connors,et al.  Coordinating emergent procedures after andexanet alfa , 2019, American journal of hematology.

[10]  J. Connors,et al.  Andexanet Alfa for Urgent Reversal of Apixaban Before Aortic Surgery Requiring Cardiopulmonary Bypass: A Case Report. , 2019, A&A practice.

[11]  Pharmd Candidate,et al.  Andexanet Alfa (Andexxa®) for the Reversal of Direct Oral Anticoagulants. , 2019, P & T : a peer-reviewed journal for formulary management.

[12]  A. Demchuk,et al.  Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors , 2019, The New England journal of medicine.

[13]  D. Pallin,et al.  Andexanet alfa—The first 150 days , 2018, American journal of hematology.

[14]  E. Mylonakis,et al.  Medicare part D prescribing for direct oral anticoagulants in the United States: Cost, use and the “rubber effect” , 2018, PloS one.

[15]  A. Rowe,et al.  Intracerebral hemorrhage after external ventricular drain placement: an evaluation of risk factors for post-procedural hemorrhagic complications , 2018, BMC Neurology.

[16]  D. Singer,et al.  Effects of Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta‐Analysis , 2017, Journal of the American Heart Association.

[17]  S. Connolly,et al.  Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. , 2015, The New England journal of medicine.

[18]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[19]  Giancarlo Agnelli,et al.  Oral apixaban for the treatment of acute venous thromboembolism. , 2013, The New England journal of medicine.

[20]  F. García-Bragado Dalmau.  [Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism]. , 2013, Revista clinica espanola.

[21]  I. Awad,et al.  External Ventricular Drainage for Intraventricular Hemorrhage , 2012, Current Neurology and Neuroscience Reports.

[22]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[23]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[24]  Bruce L Davidson,et al.  Oral rivaroxaban for symptomatic venous thromboembolism. , 2010, The New England journal of medicine.

[25]  D. Keeling,et al.  The story of the discovery of heparin and warfarin , 2008, British journal of haematology.

[26]  C. Schirmer,et al.  Decompressive Hemicraniectomy for the Treatment of Intractable Intracranial Hypertension After Aneurysmal Subarachnoid Hemorrhage , 2007, Stroke.